STOCK TITAN
  1. Home
  2. Sec-filings
  3. KRRO
  4. [Form 4] Korro Bio, Inc. Insider Trading Activity

Korro Bio (KRRO) director receives 14,677 stock options at $10.59 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Korro Bio, Inc. director Rachel Meyers received a grant of stock options as part of her compensation. The award covers 14,677 options to purchase Common Stock at an exercise price of $10.59 per share, all held directly after the transaction.

These options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, provided she continues serving as a non-employee director through that date. The options are scheduled to expire on June 9, 2036, giving a long-dated incentive aligned with the company’s share price performance.

Positive

  • None.

Negative

  • None.
Insider Meyers Rachel
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 14,677 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 14,677 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 14,677 options Stock Option (Right to Buy) grant to director Rachel Meyers
Exercise price $10.59 per share Exercise price for Korro Bio Common Stock under the option
Underlying shares 14,677 shares Common Stock underlying the option award
Post-grant derivative holdings 14,677 options Total options held following the reported transaction
Option expiration date June 9, 2036 Expiration date for the stock option grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
non-employee director financial
"subject to continued service as a non-employee director through the applicable vesting date"
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders"
vest in full financial
"The shares subject to the option vest in full on the earlier of..."
exercise price financial
"conversion_or_exercise_price: 10.5900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Meyers Rachel
(Last)(First)(Middle)
C/O KORRO BIO, INC.
60 FIRST STREET, 2ND FLOOR, SUITE 250
(Street)
CAMBRIDGE MASSACHUSETTS 02141
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$10.5906/10/2026A14,677 (1)06/09/2036Common Stock14,677$014,677D
Explanation of Responses:
1. The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.
/s/ Jeffrey Cerio, attorney-in-fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Korro Bio (KRRO) director Rachel Meyers report in this Form 4?

Rachel Meyers reported receiving a grant of stock options covering 14,677 shares of Korro Bio Common Stock. The options are a compensation award, not an open-market stock purchase or sale, and are held directly in her name following the transaction.

How many Korro Bio (KRRO) stock options did Rachel Meyers receive and at what price?

She received 14,677 stock options to buy Korro Bio Common Stock at an exercise price of $10.59 per share. This means she can purchase up to 14,677 shares at that fixed price once the options are vested and exercisable.

When do Rachel Meyers’ Korro Bio (KRRO) stock options vest?

The options vest in full on the earlier of the one-year anniversary of the grant date or the date of Korro Bio’s next annual stockholder meeting. Vesting is conditioned on her continued service as a non-employee director through the relevant vesting date.

When do Rachel Meyers’ Korro Bio (KRRO) stock options expire?

The stock options are scheduled to expire on June 9, 2036. After that expiration date, she would no longer be able to exercise them to purchase Korro Bio Common Stock at the stated $10.59 exercise price.

Is Rachel Meyers buying or selling Korro Bio (KRRO) shares in this Form 4?

She is not buying or selling shares on the open market in this Form 4. Instead, she received a compensation-related grant of stock options, which gives her the right to buy shares later at a fixed exercise price if she chooses to exercise.